US EditionData on Novo Nordisk experimental weight-loss drug show mostly mild side effects
- Novo Nordisk presented data on CagriSema, a once-weekly weight-loss drug, at the ADA's 85th Scientific Sessions in Chicago on June 22, 2025.
- The drug targets appetite and blood glucose control and was tested in two 68-week phase 3 trials called REDEFINE 1 and 2 enrolling adults with and without type 2 diabetes.
- Results showed participants lost up to 20.4% body weight in REDEFINE 1 and 13.7% in REDEFINE 2, with CagriSema outperforming placebo and semaglutide, while side effects remained mostly mild to moderate.
- Professor Carel Le Roux called the trial a turning point, stating the treatment offers hope by promoting weight loss and improved quality of life for patients managing obesity and diabetes.
- The results indicate that CagriSema has the potential to become an important new treatment for individuals managing obesity and type 2 diabetes, although Novo Nordisk's stock declined due to competitive pressures in the market.
Insights by Ground AI
Does this summary seem wrong?
23 Articles
23 Articles
All
Left
2
Center
9
Right
2
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment Pharmaceutical giant Novo Nordisk has revealed that its latest weight-loss drug, CagriSema, exhibited mostly mild-to-moderate side effects during trials, accompanied by beneficial blood sugar outcomes. Despite these positive results, investor sentiment remained negatively swayed, reflected in the downturn of Novo's share prices after the announcement.Meanwhile, riv…
·India
Read Full Article
Coverage Details
Total News Sources23
Leaning Left2Leaning Right2Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
15%
C 69%
15%
Factuality
To view factuality data please Upgrade to Premium
